A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy

Completed

Conditions studied: Hepatocellular Carcinoma

In brief

A study to describe real-world treatment patterns and overall survival in advanced liver cancer participants who received second or third line nivolumab therapy

Key facts

Study ID

NCT04161911

Run by

Bristol-Myers Squibb

People needed

1426

Starts

2018-10-29

Expected to finish

2018-11-19

Last updated by the study team

2019-11-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult aHCC participants in the Flatiron database as defined by:
• Diagnosed with HCC International Classification of Diseases (ICD)-9 155.x or ICD-10 C22.x)
• Pathology consistent with advanced HCC
• Age 18 years or older at index
• At least two clinic encounters on different days in the Flatiron database occurring on or after January 1, 2011
• Participants who received second or third line nivolumab monotherapy or combination therapy for aHCC

You may not qualify if…

• Participants with <1 month of medical data (any clinic visits, medication administrations or oral medication prescriptions) following and including the index date
• Participants with clinical study drug during prior or post study index periods
• Other protocol-defined inclusion/exclusion criteria could apply

Where it is running

• Bristol Myers Squibb, CORDS Research — Princeton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.